The Latest Cardiac and Vascular News
MINNEAPOLIS, July 30, 2024 /PRNewswire/ — VentureMed Group, Inc., a privately held medical device innovator in access management for arteriovenous (AV) fistulas and grafts and vessel preparation for interventional treatment of peripheral arterial disease (PAD) announced it has completed…
Minneapolis, Minnesota, September 6, 2023 – VentureMed Group, Inc., a privately held medical device innovator in access management for arteriovenous (AV) fistulas and grafts and vessel preparation for interventional treatment of peripheral arterial disease (PAD) announced today that the company is an early recipient of MDR certification. Gaining MDR certification […]
MINNEAPOLIS, June 15, 2022 /PRNewswire/ — VentureMed Group, Inc., a privately held medical device innovator in access management for arteriovenous (AV) fistulas and grafts and vessel preparation for interventional treatment of peripheral arterial disease (PAD) announced data presented at the Vascular Access Societies of the Americas (VASA) June 9-11, Charleston, South Carolina. Study Details and FindingsFLEX Vessel […]
MINNEAPOLIS, May 24, 2022 /PRNewswire/ — VentureMed Group, Inc., a privately held medical device innovator in access management for arteriovenous (AV) fistulas and grafts and vessel preparation for interventional treatment of peripheral arterial disease (PAD) announced today that it has completed enrollment of a randomized clinical trial (RCT) titled “FLEX Vessel Prep Prior To […]
TOLEDO, Ohio, Sept. 5, 2017 /PRNewswire/ — VentureMed Group, Inc., (“VMG” or the “Company”) a medical device company focused on developing and commercializing next-generation endovascular devices to treat peripheral arterial disease (PAD), announced today the appointment of Dave Cox as Vice President of Sales and Marketing. In this role, Mr. Cox will be responsible for […]
TOLEDO, Ohio, Aug. 15, 2017 /PRNewswire/ — VentureMed Group®, Inc., (“VMG” or the “Company”) a medical device company developing and commercializing next-generation endovascular products to treat patients suffering from peripheral artery disease (PAD), today announced it had raised $15 million in new equity financing. The Series B Round was led by new investor Endeavour […]
